RUNX2 and neoplasm: Additionally, in vivo studies were performed to assess the functional impact of the identified signaling axis on tumor progression and metastatic potential.<h4>Results</h4>Metformin treatment resulted in enhanced mTORC2 activity in a RUNX2-dependent manner, mediated through AMPK-driven stabilization of RUNX2.